PIPELINE

Current status as of May 17th 2011:

Brant Lifesciences Holding B.V. was established in December 2008. The company is in active negotiations with several parties at present including several of the priority areas listed below.

Therapeutic priorities and focus

The priorities correspond directly to the deep and successful involvement of Brant’s management and its development and manufacturing partners’ joint experiences. It is very much in our philosophy to build upon our past successes.

Brant is interested in projects which fit the following criteria in particular Therapeutic Fields:

Infectious diseases – antiviral (especially HBV/HCV/HIV), antibacterial, antifungal
Metabolic – diabetes, obesity, metabolic syndrome, lipid disorders
Biologics including vaccines and antibodies
Dermatology